Retuximab for Remission Maintenance

Retuximab has been shown in two randomized trials to have a lower rate of relapse compared to azothioprine. But the main problem remains relapse has occurred after retuximab is stopped. Concerns remain for toxicity with longer-term use, particularly hypogamoglobulinemia.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app